{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T10:37:03Z","timestamp":1786703823397,"version":"build-2736575974"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003793","name":"Swedish Heart and Lung foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011077","name":"Sk\u00e5ne University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011077","id-type":"DOI","asserted-by":"publisher"}]},{"name":"SUS Foundations and Funds"},{"DOI":"10.13039\/501100001034","name":"ALF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001034","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"publisher","award":["STYR 2019\/2046"],"award-info":[{"award-number":["STYR 2019\/2046"]}],"id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Lund University Diabetes Centre","award":["2009-1039"],"award-info":[{"award-number":["2009-1039"]}]},{"DOI":"10.13039\/501100011751","name":"Swedish Foundation for Strategic Research","doi-asserted-by":"publisher","award":["IRC15-006"],"award-info":[{"award-number":["IRC15-006"]}],"id":[{"id":"10.13039\/501100011751","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["IMI-2008\/115006"],"award-info":[{"award-number":["IMI-2008\/115006"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"name":"LeDucq Foundation Network of Excellence"},{"DOI":"10.13039\/501100014091","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014091","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019434","name":"NIHR Exeter Clinical Research Facility","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019434","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Inflammasome activation has emerged as a promising therapeutic target to reduce residual cardiovascular (CV) risk in patients on guideline lipid-lowering therapy. IL-1\u03b2 and IL-6 have been intensively studied, whereas the role of the inflammasome-related cytokine IL-18 has gained less attention. Here we aimed to assess the associations of IL-18 with risk of coronary events and severity of atherosclerosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>The study included 4742 participants participating in a prospective Swedish Malm\u00f6 Diet and Cancer (MDC) cohort study, 54 219 general population participants in the UK Biobank, and 1500 participants with Type 2 diabetes and\/or known CV disease in the European multicentre SUMMIT VIP imaging study. Plasma levels of IL-18 were analysed using proximity extension assay and atherosclerosis by carotid ultrasound. The incidence of MI and CV death was registered during a 23-year follow-up for the MDC cohort and for a 15-year follow-up for the UK Biobank cohort. There were 617 cases of MI and 644 CV deaths in the MDC cohort and 2454 cases of MI and 1537 CV deaths in the UK Biobank cohort. Elevated IL-18 was associated with an increased risk of MI and CV death independent of hsCRP and IL-6 in both cohorts. In Cox proportional hazards regression models, this association was independent of major CV risk factors in the UK Biobank but not in the MDC cohort. IL-18 did not provide clinically meaningful risk reclassification in the UK Biobank cohort. The association of IL-18 with carotid atherosclerosis in the SUMMIT VIP cohort was weaker than that of IL-6.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>IL-18 is independently associated with risk of MI and CV death in the general population but does not improve clinical risk stratification. Targeting IL-18 directly or through inflammasome inhibition represents a promising approach for treatment of residual inflammatory risk in high-risk atherosclerosis patients that merits to be evaluated in future randomized clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cvr\/cvag135","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T11:35:01Z","timestamp":1782214501000},"page":"1506-1515","source":"Crossref","is-referenced-by-count":1,"title":["Associations of the inflammasome-dependent cytokine IL-18 with risk of coronary heart disease"],"prefix":"10.1093","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3918-0857","authenticated-orcid":false,"given":"Harry","family":"Bj\u00f6rkbacka","sequence":"first","affiliation":[{"name":"Department of Clinical Sciences Malm\u00f6, Lund University ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2935-0181","authenticated-orcid":false,"given":"Isabel","family":"Gon\u00e7alves","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences Malm\u00f6, Lund University ,","place":["Sweden"]},{"name":"Department of Cardiology, Sk\u00e5ne University Hospital , Jan Waldenstr\u00f6ms gata 35, 21428 Malm\u00f6 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8618-9152","authenticated-orcid":false,"given":"Gunnar","family":"Engstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences Malm\u00f6, Lund University ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7587-5050","authenticated-orcid":false,"given":"Alexandru","family":"Schiopu","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, Lund University , Malm\u00f6 ,","place":["Sweden"]},{"name":"Nicolae Simionescu Institute of Cellular Biology and Pathology , Bucharest ,","place":["Romania"]},{"name":"Department of Internal Medicine, Sk\u00e5ne University Hospital , Lund ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"von Sydow","sequence":"additional","affiliation":[{"name":"AstraZeneca , M\u00f6lndal ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Ryaboshapkina","sequence":"additional","affiliation":[{"name":"AstraZeneca , M\u00f6lndal ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijayalakshmi","family":"Varma","sequence":"additional","affiliation":[{"name":"AstraZeneca , Gaithersburg ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair","family":"Moss","sequence":"additional","affiliation":[{"name":"AstraZeneca , Cambridge ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela C","family":"Shore","sequence":"additional","affiliation":[{"name":"Diabetes and Vascular Medicine, University of Exeter Medical School and NIHR Exeter Clinical Research Facility , Exeter ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8465-7717","authenticated-orcid":false,"given":"Andrea","family":"Natali","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Pisa , Pisa ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9889-0229","authenticated-orcid":false,"given":"Faisel","family":"Khan","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Research, University of Dundee , Dundee ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9752-7479","authenticated-orcid":false,"given":"Jan","family":"Nilsson","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences Malm\u00f6, Lund University ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"2026081406120548700_cvag135-B1","doi-asserted-by":"crossref","DOI":"10.1016\/j.vph.2023.107238","article-title":"Targeting residual inflammatory risk: the next frontier for atherosclerosis treatment and prevention","volume":"153","author":"Ridker","year":"2023","journal-title":"Vascul Pharmacol"},{"key":"2026081406120548700_cvag135-B2","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"2026081406120548700_cvag135-B3","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"2026081406120548700_cvag135-B4","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Lodoco2 trial I. Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med"},{"key":"2026081406120548700_cvag135-B5","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nri.2016.58","article-title":"Inflammasomes: mechanism of assembly, regulation and signalling","volume":"16","author":"Broz","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"2026081406120548700_cvag135-B6","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/CIRCRESAHA.115.306656","article-title":"From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection","volume":"118","author":"Ridker","year":"2016","journal-title":"Circ Res"},{"key":"2026081406120548700_cvag135-B7","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1161\/CIRCRESAHA.121.319077","article-title":"Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease","volume":"128","author":"Ridker","year":"2021","journal-title":"Circ Res"},{"key":"2026081406120548700_cvag135-B8","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/MOL.0b013e3283307bfe","article-title":"Does elevated C-reactive protein cause human atherothrombosis? Novel insights from genetics, intervention trials, and elsewhere","volume":"20","author":"Nordestgaard","year":"2009","journal-title":"Curr Opin Lipidol"},{"key":"2026081406120548700_cvag135-B9","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.108053","article-title":"Targeting the NLRP3 inflammasome in cardiovascular diseases","volume":"236","author":"Toldo","year":"2022","journal-title":"Pharmacol Ther"},{"key":"2026081406120548700_cvag135-B10","doi-asserted-by":"crossref","first-page":"E41","DOI":"10.1161\/hh1901.098735","article-title":"Interleukin-18\/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability","volume":"89","author":"Mallat","year":"2001","journal-title":"Circ Res"},{"key":"2026081406120548700_cvag135-B11","doi-asserted-by":"crossref","first-page":"E34","DOI":"10.1161\/hh0202.105292","article-title":"Interleukin-18 enhances atherosclerosis in apolipoprotein E(-\/-) mice through release of interferon-gamma","volume":"90","author":"Whitman","year":"2002","journal-title":"Circ Res"},{"key":"2026081406120548700_cvag135-B12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1365-2796.1993.tb00647.x","article-title":"The Malmo Diet and Cancer Study. Design and feasibility","volume":"233","author":"Berglund","year":"1993","journal-title":"J Intern Med"},{"key":"2026081406120548700_cvag135-B13","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1464-5491.2000.00280.x","article-title":"Relation between insulin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects. Results from a cross-sectional study in Malmo, Sweden","volume":"17","author":"Hedblad","year":"2000","journal-title":"Diabet Med"},{"key":"2026081406120548700_cvag135-B14","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/joim.12359","article-title":"Measures of atherosclerotic burden are associated with clinically manifest cardiovascular disease in type 2 diabetes: a European cross-sectional study","volume":"278","author":"Shore","year":"2015","journal-title":"J Intern Med"},{"key":"2026081406120548700_cvag135-B15","article-title":"Plaque characteristics and biomarkers predicting regression and progression of carotid atherosclerosis","volume":"3","author":"Khan","year":"2022","journal-title":"Cell Rep Med"},{"key":"2026081406120548700_cvag135-B16","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41586-023-06592-6","article-title":"Plasma proteomic associations with genetics and health in the UK Biobank","volume":"622","author":"Sun","year":"2023","journal-title":"Nature"},{"key":"2026081406120548700_cvag135-B17","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1161\/01.STR.0000147038.12073.59","article-title":"Elastin and calcium rather than collagen or lipid content are associated with echogenicity of human carotid plaques","volume":"35","author":"Goncalves","year":"2004","journal-title":"Stroke"},{"key":"2026081406120548700_cvag135-B18","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1161\/ATVBAHA.119.313032","article-title":"Low levels of CD4(+)CD28(null) T cells at baseline are associated with first-time coronary events in a prospective population-based case-control cohort","volume":"40","author":"Tomas","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026081406120548700_cvag135-B19","doi-asserted-by":"crossref","DOI":"10.21105\/joss.01317","article-title":"Lifelines: survival analysis in Python","volume":"4","author":"Davidson-Pilon","year":"2019","journal-title":"J Open Source Softw"},{"key":"2026081406120548700_cvag135-B20","doi-asserted-by":"crossref","DOI":"10.1016\/j.vph.2023.107214","article-title":"Circulating soluble IL-6 receptor associates with plaque inflammation but not with atherosclerosis severity and cardiovascular risk","volume":"152","author":"Edsfeldt","year":"2023","journal-title":"Vascul Pharmacol"},{"key":"2026081406120548700_cvag135-B21","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1161\/01.CIR.0000099509.76044.A2","article-title":"Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME)","volume":"108","author":"Blankenberg","year":"2003","journal-title":"Circulation"},{"key":"2026081406120548700_cvag135-B22","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/eurjpc\/zwad197","article-title":"Association of interleukin-6 and interleukin-18 with cardiovascular disease in older adults: atherosclerosis risk in communities study","volume":"30","author":"Jia","year":"2023","journal-title":"Eur J Prev Cardiol"},{"key":"2026081406120548700_cvag135-B23","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1161\/hc2601.091704","article-title":"Ultrasonic echolucent carotid plaques predict future strokes","volume":"104","author":"Gronholdt","year":"2001","journal-title":"Circulation"},{"key":"2026081406120548700_cvag135-B24","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jacc.2019.07.012","article-title":"Large-artery stiffness in health and disease: JACC State-of-the-Art Review","volume":"74","author":"Chirinos","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026081406120548700_cvag135-B25","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.immuni.2013.06.009","article-title":"Immune effector mechanisms implicated in atherosclerosis: from mice to humans","volume":"38","author":"Libby","year":"2013","journal-title":"Immunity"},{"key":"2026081406120548700_cvag135-B26","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41584-023-01053-w","article-title":"Biological and clinical roles of IL-18 in inflammatory diseases","volume":"20","author":"Landy","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"2026081406120548700_cvag135-B27","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jjcc.2024.03.003","article-title":"The role of the NLRP3 inflammasome in atherosclerotic disease: systematic review and meta-analysis","volume":"84","author":"Khair","year":"2024","journal-title":"J Cardiol"},{"key":"2026081406120548700_cvag135-B28","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11883-024-01259-7","article-title":"IL-6 and cardiovascular risk: a narrative review","volume":"27","author":"Mehta","year":"2024","journal-title":"Curr Atheroscler Rep"},{"key":"2026081406120548700_cvag135-B29","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.atherosclerosis.2011.03.015","article-title":"Interleukin 18 and coronary heart disease: prospective study and systematic review","volume":"217","author":"Jefferis","year":"2011","journal-title":"Atherosclerosis"},{"key":"2026081406120548700_cvag135-B30","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1093\/eurjpc\/zwae124","article-title":"Large-scale plasma proteomics in the UK Biobank modestly improves prediction of major cardiovascular events in a population without previous cardiovascular disease","volume":"31","author":"Royer","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2026081406120548700_cvag135-B31","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","article-title":"Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial","volume":"391","author":"Ridker","year":"2018","journal-title":"Lancet"},{"key":"2026081406120548700_cvag135-B32","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1093\/eurheartj\/ehz542","article-title":"Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1beta inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis","volume":"41","author":"Ridker","year":"2020","journal-title":"Eur Heart J"},{"key":"2026081406120548700_cvag135-B33","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1161\/CIRCULATIONAHA.124.072238","article-title":"Genetically predicted IL-18 inhibition and risk of cardiovascular events: a Mendelian randomization study","volume":"151","author":"Brennan","year":"2025","journal-title":"Circulation"},{"key":"2026081406120548700_cvag135-B34","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1161\/hc3901.096721","article-title":"Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability","volume":"104","author":"Mallat","year":"2001","journal-title":"Circulation"},{"key":"2026081406120548700_cvag135-B35","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.003031","article-title":"NLRP3 inflammasome expression and activation in human atherosclerosis","volume":"5","author":"Paramel Varghese","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"2026081406120548700_cvag135-B36","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252413505","article-title":"IL-18 and IL-18BP: a unique dyad in health and disease","volume":"25","author":"Novick","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026081406120548700_cvag135-B37","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1161\/01.ATV.0000168417.52486.56","article-title":"Associations of serum IL-18 levels with carotid intima-media thickness","volume":"25","author":"Yamagami","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026081406120548700_cvag135-B38","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.2337\/diacare.28.12.2890","article-title":"Serum interleukin-18 levels are associated with nephropathy and atherosclerosis in Japanese patients with type 2 diabetes","volume":"28","author":"Nakamura","year":"2005","journal-title":"Diabetes Care"},{"key":"2026081406120548700_cvag135-B39","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3390\/cells10010037","article-title":"CD8(+) T Cells in Atherosclerosis","volume":"10","author":"Schafer","year":"2020","journal-title":"Cells"}],"container-title":["Cardiovascular Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cardiovascres\/advance-article-pdf\/doi\/10.1093\/cvr\/cvag135\/68583837\/cvag135.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article-pdf\/122\/11\/1506\/68583837\/cvag135.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article-pdf\/122\/11\/1506\/68583837\/cvag135.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T10:13:24Z","timestamp":1786702404000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article\/122\/11\/1506\/8713803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":39,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,6,23]]},"published-print":{"date-parts":[[2026,8,14]]}},"URL":"https:\/\/doi.org\/10.1093\/cvr\/cvag135","relation":{},"ISSN":["0008-6363","1755-3245"],"issn-type":[{"value":"0008-6363","type":"print"},{"value":"1755-3245","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,6,23]]}}}